Hikma Pharma gets USFDA nod for Kloxxado nasal spray
London: Hikma Pharmaceuticals PLC has recently announced the approval of KLOXXADO (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration (USFDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
KLOXXADO contains twice as much naloxone per spray as Narcan Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.
Drug overdose, including most commonly opioid overdose, has been described as the "leading cause of accidental death" in the US today – a situation that has been exacerbated by the COVID-19 pandemic. According to health organizations, widely prescribing and distributing naloxone may play a vital role in the fight against opioid overdose. With the increasing prevalence of illicitly manufactured synthetic opioids, a higher dose of naloxone may be required to revive a patient.
In a survey of community organizations to which Narcan Nasal Spray 4mg had been distributed, 34% of attempted reversals used two or more doses. Additionally, a separate study published in 2019 found that the percent of overdose-related EMS calls in the US requiring multiple doses of naloxone during 2013-2016 had increased to 21%, representing a 43% increase over those four years.
"The approval of KLOXXADO is an important step in providing patients, friends and family members – as well as the public health community – with an important new option for treating opioid overdose," said Brian Hoffmann, President, Hikma Generics. "As an experienced provider of addiction therapy treatments and a leading producer of nasal sprays in the US, we are pleased to leverage our capabilities to deliver an important new tool in the fight against opioid overdose."
Hikma expects KLOXXADO to be available in the second half of 2021.
Read also: USFDA grants EUA to Thermo Fisher Scientific's Amplitude Solution for COVID-19 testing
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.